Trial
NCT00462202
Open Label Tolerability and Safety Study of KRX-101 in Australia, New Zealand, and Hong Kong
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Keryx Biopharmaceuticals
Collaborators
Collaborative Study Group (CSG)
Condition
Diabetic Nephropathy
Intervention
sulodexide
Why stopped
Interim analysis of efficacy trial showed no drug efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-03